PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Evan A. Stein et al.|The Lancet|2014Cited by 750
A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaDirk Blom, Evan A. Stein, R Češka et al.|New England Journal of Medicine|2014Cited by 712
Evinacumab in Patients with Refractory HypercholesterolemiaRobert S. Rosenson, Daniel Gaudet, Lesley Burgess et al.|New England Journal of Medicine|2020Cited by 294